TheraVet lists on Euronext Growth Paris and Brussels

Back

€7 million raised – market capitalisation of approx. €31 million

Brussels and Paris – 17 June 2021 – Euronext today congratulates TheraVet, a vet biotech company developing new treatments specifically adapted to pets, on its dual listing on Euronext Growth® Paris and Euronext Growth® Brussels (ticker code: ALVET).

Headquartered in Belgium (Jumet, Wallonia) with an US-based subsidiary, TheraVet's mission is to develop innovative, safe and effective treatments to improve the well-being and quality of life of companion animals suffering from osteoarticular diseases. TheraVet's main targets (indications & applications) are bone surgery with BIOCERA-VET product line in cats and dogs as well as horses and osteoarthritis & ligament & tendon injuries with VISCO-VET product line in dogs.

TheraVet was listed through the admission to trading of the 3,223,936 shares making up its equity, including 734,636 new shares issued under a Public Offering.

The admission and issue price of TheraVet shares was set at €9.60 per share. Market capitalisation was €30.9 million on the day of listing. The offering raised €7.05 million altogether.

Enrico Bastianelli, Founder and CEO of TheraVet, said: “We are proud of the success achieved by TheraVet’s IPO on Euronext Growth Paris et Brussels, and we offer our sincere thanks to all of our new retail and institutional shareholders. We specialise in osteoarticular treatments and we now have the financial resources we need to carry out clinical development in our two product ranges and to market them in Europe and the United States.” 

Theravet

Caption: Enrico Bastianelli, Founder and CEO of TheraVet, and his team rang the bell during a ceremony this morning together with Vincent Van Dessel, CEO of Euronext Brussels, to celebrate the Initial Public Offering of the company.

About TheraVet TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris et Brussels, its head office is in Jumet, Belgium, and it has a subsidiary in the US. For more information, visit www.thera.vet

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.